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Efficacy Evaluation in the Era of
Precision Medicine: The Scope
for AI
Dominic Magirr
Abstract
Patient stratification and the use of real-world evidence in regulatory decision-
making are two key areas where algorithms are having an impact on drug develop-
ment. The two are linked: increased patient stratification makes it harder to recruit
patients into randomized-controlled trials, increasing the pressure on drug devel-
opers to find alternative sources of evidence for showing efficacy. In addition to
real-world evidence, we are also seeing the emergence of more efficient ‘master
protocol trials’, where multiple targeted agents can be evaluated simultaneously.
In this chapter, I will review these developments and investigate the limitations for
AI in terms of demonstrating the efficacy of novel targeted agents.
Keywords: drug development, precision medicine, statistics
1. Introduction
The use of algorithms to find patterns and make predictions from multiple data
sources—here referred to as artificial intelligence (AI)—is having an increasingly
large impact on clinical drug development.
Algorithms can be applied to combined clinical and genetic data sets to stratify
patient populations into subgroups, based on shared characteristics or similar prog-
nostic profiles [1–2]. This would appear to make sense, since the majority of new
drugs approved by the US FDA in recent years have been targeted towards specific
genetic aberrations [3–4]. If we increase our search, we will find more genetic
aberrations, more drug targets, and more potentially efficacious drugs. However,
this approach also presents severe challenges in the clinical stages of drug develop-
ment, as the size, complexity and duration of studies increases.
One way to react to increased cost and duration is to improve the operational
efficiency of clinical trials. The last decade has seen the emergence of ‘master
protocol trials’, which allow several substudies to be conducted simultaneously,
reducing the rate of screen failures [5]. In addition, there is increasing enthusiasm
for augmenting (possibly even replacing) randomized-controlled trials (RCTs) with
external and real-world data, where it is claimed that further use of algorithms can
protect us from the biases that this approach would otherwise impose [1].
The purpose of this article is three-fold. Firstly, to explain how precision medi-
cine presents challenges to traditional drug development, quantifying the effect of
disease stratification on trial recruitment. Secondly, to describe how master
1
protocol studies have emerged in response to these challenges. Finally, to explore
whether it is possible for single-arm studies with ‘synthetic control arms’ to provide
the same standard of evidence as a randomized controlled trial, thus reducing
drug development timelines.
2. Disease stratification
Consider a patient population that can be stratified according to the value of a
diagnostic test. The ‘target’ population consists of patients who test positive. The
‘non-target’ population consists of patients who do not test positive. Suppose that
a new treatment is expected to be more effective in the target population than in the
non-target population. Let θþ and let θ denote the treatment effect sizes in target
and non-target populations, and γ denote the prevalence of the target group. Three
things that we would like to demonstrate are:
1.Treatment benefit in the full population, γθþ þ 1 γð Þθ >0.
2.Treatment benefit in the target population, θþ >0.
3.Greater benefit in the target population than in the non-target population,
θþ > θ.
Which of these is easiest to demonstrate, and which most difficult? To answer
this, we compare the standardised statistics, Z, that we would use to test the
corresponding null hypotheses. For most commonly-used clinical-trial endpoints,
the test statistic ends up looking like
Z  N θ
ffiffi
I
p
, 1
 
, (1)
where θ is the treatment effect size and I is the statistical information, which is
typically proportional to the sample size [6, 7]. The power of a test is the probability
that Z > k, for a threshold k, where k is chosen to ensure a given false-positive rate.
The larger the expected value of Z, the higher the power. Therefore two trials (‘A’
and ‘B’) will have the same power if θA
ffiffiffiffiffi
IA
p ¼ θB
ffiffiffiffi
IB
p
, or, assuming that information
is proportional to sample size, if
θA
ffiffiffiffiffiffiffi
NA
p
¼ θB
ffiffiffiffiffiffi
NB
p
: (2)
We can use (2) to assess the relative difficulty of our three goals, firstly for the
full population versus the interaction (1. versus 3.), and then for the full population
versus the target population (1. versus 2.).
2.1 Full population versus interaction
It is shown in the appendix that a test of the interaction null hypothesis, θþ ¼ θ,
with total sample sizeNint, will have the same power as the test for the full population
null hypothesis, γθþ þ 1 γð Þθ ¼ 0, with sample size N, provided that
θþ  θð Þ
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
γ 1 γð ÞNint
p
¼ γθþ þ 1 γð Þθf g
ffiffiffiffi
N
p
: (3)
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For example, when θ=θþ ¼ 0:5, for a prevalence of 50%, the ratio of sample
sizes is Nint=N ¼ 9. For a prevalence of 5%, Nint=N ≈ 23. This shows how difficult it
is to provide compelling evidence for treatment-biomarker interactions, and why
drug development is still focussed on demonstrating average treatment effects. It is
also explains why post-hoc data-driven subgroup identification following a clinical
trial is often a bad idea. See Gelman [8] for further discussion.
2.2 Full population versus target population
A test for the full population null hypothesis with sample size N will have the
same power as a test for the target population null hypothesis, θþ ¼ 0, with sample
size NT, provided that
γθþ þ 1 γð Þθf g
ffiffiffiffi
N
p
¼ θþ
ffiffiffiffiffiffiffi
NT
p
, (4)
or, equivalently, if
NT
N
¼ γ þ 1 γð Þ θ

θþ
 2
: (5)
In (5), we have expressed the relative sample size, NT=N, as a function of the
relative efficacy, θ=θþ [9]. This relationship is drawn in solid lines in Figure 1 for
two potential prevalences (50% and 5%) when θ=θþ is between 0.5 and 1. For a
prevalence of 50%, the targeted strategy requires up to 40% fewer patients than the
non-targeted strategy. For a prevalence of 5%, a 70% reduction is possible. Note,
however, that this is the relative number of patients enrolled. What about the
Figure 1.
Relative sample size when testing efficacy in the target population compared to the full population (NT=N),
shown in solid lines. The dashed lines show the relative number of patients screened ( NT=γð Þ=N).
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number of patients screened? In the full population the minimum number screened
is N, whereas in the targeted population it is Nt divided by γ. The ratio, Nt=γð Þ=N, is
drawn in dashed lines in Figure 1. For the 50% prevalence case, there is a maximum
2-fold increase in the number screened for the targeted compared to the non-
targeted trial. But for the 5% prevalence case, there is somewhere between a six-fold
and a twenty-fold increase.
2.3 Situations where θ≪ θþ
The conclusion from Figure 1 is that population stratification is only likely to be
useful if there exists a potential treatment where the treatment effect is consider-
ably higher (e.g. at least two-fold) in the target subgroup than in the rest of the
population. Marginal increases in efficacy are not enough in practice. The targeted
approach would require a prohibitively large number of patients to be screened,
compared to a trial in the full population which would have the same statistical
power. Marginal increases are also difficult to establish empirically, as shown in
Section 2.1. It follows that successful implementation of precision-medicine drug
development is restricted to situations where there is strong biological and pre-
clinical evidence for expecting θ≪ θþ. Such cases certainly do exist, and the
targeted trial is the only sensible approach here. Nevertheless, one still needs to
screen a very high number of patients. This is expensive for the sponsor. It is also
disheartening for patients who do not meet the eligibility criteria.
3. Master protocol trials
The high screen failure rate of precision-medicine trials can be mitigated to some
extent by merging multiple sub-studies into a single ‘master protocol’. The last
decade has seen the emergence of the labels ‘basket’ and ‘umbrella’ to describe these
complex studies. As a rule of thumb, a basket tends to refer to studies involving the
same drug in multiple diseases, whereas umbrella is used when multiple experi-
mental treatments are studied in the same disease. However, as reported by Janiaud
and colleagues [10], these terms have not been applied consistently. Their system-
atic review of master protocol trials in oncology found 30 ‘basket’ trials and 27
‘umbrella’ trials in a time period of 2006–2018, but with most studies starting after
2015. They explain that some basket trials are mistakenly labeled as umbrella trials,
and vice-versa, but there are also trials that contain elements of both and thus
become difficult to describe using current language.
Stallard and colleagues [11] propose a refined classification which replaces
ambiguous labels with a more precise visual description, as shown in Figure 2. In
each of the six designs, a small square is representative of a cohort of patients. On
the left hand side are the basket-type designs, where there is only one new treat-
ment (T) targeting a particular mutation (M), but this mutation occurs across
diseases (D1,D2, … ). In the middle are the umbrella-type designs, where there are
multiple treatments (T1,T2, … ) targeting particular mutations (M1,M2, … ), all
within the same overall disease (D). The designs on the right hand side combine the
features of the basket-type and umbrella-type designs. They allow for multiple
disease types within each of the separate treatment-mutation combinations. Note,
however, that it is always the mutation that is driving the choice of treatment,
rather than the disease type. In all of the designs, for each T-M-D sub-study, it is
possible to use a single-arm design (Figure 2a), or compare with a concurrent
control arm (Figure 2b).
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3.1 Example 1: Vemurafenib in cancers (not melanoma) with BRAF V600
mutations
Hyman and colleagues [12] report the results of a basket-type study with the
same structure as the left-hand-side of Figure 2a. The treatment (T) was
Vemurafenib, the mutation (M) was BRAF V600. There were several cohorts
corresponding to different disease types (D):
• Colorectal cancer (CRC)
• Bile duct cancer
• Anaplastic thyroid cancer (ATC)
• Non-small cell lung cancer (NSCLC)
• Erdheim-Chester disease/Langerhans cell histiocytosis (ECD/LCH)
Figure 2.
A classification of master protocol designs by Stallard and colleagues [11]. Each square represents a cohort of
patients. (a) Single-arm cohorts. (b) Concurrent control arms.
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A Simon’s two-stage design [13] was used for each cohort independently to allow
for early futility stopping. Consequently, the cohort sizes ranged from 5 to 27.
Hobbs and colleagues [14], did a re-analysis of the data, and their findings are
reproduced in Figure 3. Looking at the response rate across cohorts, it appears that
there is more activity in NSCLC and ECD/LCH than in CRC. However, one can also
see a clear inverse relationship between response rate and number of prior thera-
pies, which muddies the water. This example highlights how difficult it can be to
interpret uncontrolled studies.
3.2 Example 2: FOCUS4
An example of a master protocol trial that does include concurrent control arms
is FOCUS4 [15], currently being run by the Medical Research Council Clinical Trials
Unit in London. It has an umbrella-type design like Figure 2b. The disease setting
(D) is advanced colorectal cancer. Mutations (M) include:
• BRAF mutations
• MSI deficient
• PIK3CA mutations
• Wild type
A centralised molecular analysis is performed on each patients tumor. Based on
the results, patients are offered entry into an appropriate substudy, where they are
randomized to receive either an experimental treatment (T) targeted to their
mutation, or a control treatment.
Figure 3.
Results from a basket-type study of Vemuarafenib [12–13].
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The substudies will be analysed independently, as if they were separate trials.
The big advantage over independent studies is the increased efficiency from the
centralised molecular analysis, ensuring fewer screen failures. Complications may
arise when patients are eligible for more than one substudy, and this has to be
planned for in the protocol. Note also the inclusion of the Wild-type cohort in
FOCUS4. This maximizes the proportion of patients who undergo screening who
are given an option to go on a trial.
4. External control arms
Precision medicine is increasing the pressure on drug developers to find inno-
vative ways to demonstrate efficacy without requiring ever larger and lengthier
clinical trials. We have seen how operational efficiencies can be found in master
protocol trials. A related development is the use of ‘big data’—the bringing together
of historical RCT data, electronic health records, advanced statistical modeling, and
machine-learning—to produce a historical benchmark, or even a so-called ‘syn-
thetic control arm’, that might allow a single-arm study to take the place of an RCT
as a basis for seeking drug approval.
For this approach to be successful, the key use-case in oncology is a comparison
of overall survival (OS). It is typical for inference to focus on the (log) hazard ratio,
θ≔ log
λE tð Þ
λC tð Þ , (6)
where it is assumed that the hazard of death on the experimental arm, λE tð Þ, is
proportional to the hazard of death on the control arm, λC tð Þ, for all timepoints t.
Another way to describe λ tð Þ is that it is your risk of dying on day t given that you were
alive atmidnight.More stringent than proportional hazards is an assumption of constant
hazards, λj tð Þ ¼ λj for all t (j ¼ E,C). Although an over-simplification, this model is
often not a bad approximation to reality, and we will use it to compare operating
characteristics for a two-armRCT versus a single-arm trial with an external control arm.
4.1 Distribution of treatment effect estimators
The constant-hazards assumption allows us to express the log hazard ratio as the
difference between the log-transformed median survival times,
log
λE
λC
¼ logmC  logmE: (7)
For a two-arm study with equal randomisation and D events, the estimate of the
log hazard ratio has the following (approximate) distribution:
θ^ ¼ log m^C  log m^E  N θ, 4=Dð Þ: (8)
If we were to run a single-arm study instead, but keep the overall sample size the
same, i.e. put all patients who would have received the control treatment onto the
experimental arm, we could use the test statistic
θ^
∗ ¼ logm ∗C  log m^E  N θ þ logm ∗C  logmC, 1=D
 
(9)
where m ∗C is our best pre-trial estimate for the median OS on the control arm.
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4.2 Bias-variance trade-off
We can compare the precision of the two estimates in terms of their mean-
squared-errors,
mse θ^
  ¼ var θ^ þ bias θ^ 2
¼ 4=Dþ 0
(10)
and
mse θ^
∗
 
¼ var θ^ ∗
 
þ bias θ^ ∗
 2
¼ 1=Dþ logm ∗C  logmC
		 		2:
(11)
For low values of D, variance will be a bigger problem than bias. In this case,
mse θ^
∗
 
<mse θ^
 
. However, as soon as
D>
3
logm ∗C  logmC
		 		2 (12)
the bias will dominate, and the estimate from the two-arm trial will be more
precise.
4.3 NSCLC example
What is a typical value for ∣ logm ∗C  logmC∣? This depends on the context. The
FDA have published data from 14 large randomized control trials [16] in advanced
non-small-cell-lung cancer (NSCLC) conducted between 2003 and 2015. The
median survival on the control arm across the studies is shown in Figure 4. Three of
the studies were targeted towards patients with a particular biomarker. It is imme-
diately obvious that these three data points are different from the rest, and this
highlights the dangerous territory we are in. Nevertheless, if we focus on the 11
studies that did not use a targeted approach, the median overall survival ranged
from 7 to 13 months. Taking an average value, a sensible choice for logm ∗C is
log 9:5ð Þ. We could also think about the ‘true’ logmC for the current study belong-
ing to the same distribution as the 11 other studies, which we might approximate
with a normal distribution
logmC  N logm ∗C ¼ log 9:5ð Þ, σ2mC ¼ 0:03
 
(13)
The expected value of ∣ logm ∗C  logmC∣ according to (13) is
ffiffiffiffiffiffiffi
2=pi
p
σmC ≈0:14.
Plugging this into (12), the two-arm trial would be more precise than the single-arm
trial when D> 153.
4.4 Reducing the sample size
What if instead of moving patients from the control arm to the experimental
arm and keeping total sample size the same, we run a single-arm study with half
the number of patients, i.e. we keep the same sample size on the experimental
arm and replace the control arm with an historical benchmark? In this case, the
8
Artificial Intelligence in Oncology Drug Discovery and Development
mean-squared-error of the estimate from the two-arm trial will be lower than the
single-arm equivalent as soon as
D>
2
logm ∗C  logmC
		 		2, (14)
where D is the number of events in the two-arm trial. For our lung cancer
example, this would mean as soon as D> 102.
4.5 More advanced methods
In the previous example we were using the average value from 11 previous
studies as a rather crude estimate of logm ∗C . Is it possible to improve the precision
using ‘big data’—bringing together historical RCT data, electronic health records,
advanced statistical modeling, and machine-learning?
We can look to a recent study by Carrigan and colleagues [17]. The group had
access to individual patient data from 9 RCTs in advanced NSCLC conducted
between 2011 and 2018, as well as electronic health records (EHR) from almost
50,000 patients. They used advanced regression and stratification techniques to
estimate treatment effect sizes, and their results are reproduced on the left hand
side of Figure 5. There is a high correlation (0.86) between the hazard ratio from
Figure 4.
Between-trial variability in median overall survival time from 14 phase 3 studies in advanced non-small-cell
lung cancer trials submitted to the FDA [16].
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the RCTs and the hazard ratio that would have been observed had the control arm
been replaced with electronic health record data. On the right hand side, the data
points have been transformed into an estimate of the bias ∣ logm ∗C  logmC∣,
assuming constant hazards. The mean value is 0.1 and according to (12) this means
that a two-arm trial would be more precise than a single-arm trial of the same total
sample size whenever D> 300. Similarly, using (14), a two-arm trial will be more
precise than a single-arm trial with half the sample size when D> 200.
To put these findings in some context, for a study with one-sided type-1 error of
α ¼ 0:025, 300 events would give 90% power when HR ¼ 0:69. Likewise, 100
events would give 90% power when HR ¼ 0:52.
5. Conclusions
Advances in pattern-recognition and prediction algorithms have the potential to
improve health outcomes, as well as making the drug development process more
efficient. Nevertheless, it is important to have a strong grasp of some limiting
factors, to avoiding spending time on futile endeavors.
The stratification of patient populations into ever finer subgroups is only likely
to prove useful when there exist potential treatments with very large differential
treatment effects. Marginal is not enough—it needs to be 100% more efficacious in
the target subgroup than in the non-target subgroup. Otherwise, a clinical trial in
the full population would have the same statistical power with far fewer patients
screened. This means that we need strong biological rationale and robust pre-
clinical evidence. In addition, it is essential that the diagnostic test has high sensi-
tivity and specificity. Otherwise, a large treatment effect in the true biomarker-
positive population would become diluted in the observed biomarker-positive popu-
lation.
In cases where there is a strong rationale for a targeted approach, recruitment
will be challenging. Master protocol trials can be an excellent option. They are an
efficient way to test novel agents, and they increase the chance that a patient
entering screening will be able to join a clinical trial.
Improvements in the quality of electronic health records, as well as better algo-
rithms to interrogate this data, are a positive development that can enhance our
Figure 5.
Correlation between RCT-derived and EHR-derived hazard ratios from nine studies in advanced non-small-
cell lung cancer [17]. On the right-hand-side, the results have been converted into an approximation of the bias
when estimating the median survival time on the control arm using EHR data.
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understanding of health outcomes, and help enormously with clinical trial design
and interpretation. Nevertheless, we should not forget the fundamental benefits of
concurrent control [18], and should remain realistic about the ability of synthetic
control arms to replace the real thing. We have seen that under favorable circum-
stances (highly prevalent disease, patient-level data from numerous high-quality
large RCTs, tens of thousands of electronic health records, well-defined and
accurately-measured primary endpoint, careful analysis), a single-arm study can
provide similar precision to a two-arm randomized comparison with sample size in
the low hundreds [17]. It is plausible, therefore, that for a new drug in this space
with a very large treatment effect, a single-arm study may provide convincing
evidence of efficacy. But one should expect this to be the exception, not the norm.
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Appendix
Based on the test statistics (1) for the target and non-target populations,
Zþ  N θþ
ffiffiffiffiffiffiffiffi
γIint
p
, 1
 
and
Z  N θ
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1 γð ÞIint
p
, 1
 
,
we can define an interaction test statistic
Zint≔
ffiffiffiffiffiffiffiffiffiffi
1 γ
p
Zþ  ffiffiγp Z  N θþ  θð Þ ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiγ 1 γð ÞIintp , 1
 
:
By (2), this test will have the same power as the full population test with sample
size N if
θþ  θð Þ
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
γ 1 γð ÞNint
p
¼ γθþ þ 1 γð Þθf g
ffiffiffiffi
N
p
:
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